Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cancers arise from multiple acquired mutations, which presumably occur over many years. Early stages in cancer development might be present years before cancers become clinically apparent. METHODS: We analyzed data from whole-exome sequencing of DNA in peripheral-blood cells from 12,380 persons, unselected for cancer or hematologic phenotypes. We identified somatic mutations on the basis of unusual allelic fractions. We used data from Swedish national patient registers to follow health outcomes for 2 to 7 years after DNA sampling. RESULTS: Clonal hematopoiesis with somatic mutations was observed in 10% of persons older than 65 years of age but in only 1% of those younger than 50 years of age. Detectable clonal expansions most frequently involved somatic mutations in three genes (DNMT3A, ASXL1, and TET2) that have previously been implicated in hematologic cancers. Clonal hematopoiesis was a strong risk factor for subsequent hematologic cancer (hazard ratio, 12.9; 95% confidence interval, 5.8 to 28.7). Approximately 42% of hematologic cancers in this cohort arose in persons who had clonality at the time of DNA sampling, more than 6 months before a first diagnosis of cancer. Analysis of bone marrow-biopsy specimens obtained from two patients at the time of diagnosis of acute myeloid leukemia revealed that their cancers arose from the earlier clones. CONCLUSIONS: Clonal hematopoiesis with somatic mutations is readily detected by means of DNA sequencing, is increasingly common as people age, and is associated with increased risks of hematologic cancer and death. A subset of the genes that are mutated in patients with myeloid cancers is frequently mutated in apparently healthy persons; these mutations may represent characteristic early events in the development of hematologic cancers. (Funded by the National Human Genome Research Institute and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clonal expansion of blood cells, called clonal hematopoiesis (CH), increases in prevalence with age and is associated with increased risk of hematologic malignancies, but also unexpectedly with increased risk of cardiovascular disease20,21, likely through inflammatory effects of mutant cells22.”
From Somatic cancer variants enriched in Alzheimer’s disease microglia-like cells drive inflammatory and proliferative states (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This state of abnormal HSC expansion without overt hematologic disease is known as clonal hematopoiesis (CH), and is associated with increased risk of cardiovascular events and blood cancers (3)(4)(5).”
From Txnip Enhances Fitness of Dnmt3a -Mutant Hematopoietic Stem Cells via p21 (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function heterozygous mutations in epigenetic regulators DNMT3A (cytosine methyltransferase) and TET2 (methylcytosine dioxygenase) are the most frequently detected mutations in CHIP, accounting for about 50% to 60% and 10% to 30% of mutations found in CHIP carriers, respectively.1, 2, 3,7,8”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Experimental — accuracy not yet measured
21 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470 · cited 15×
“Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.”
BackgroundInfluentialDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Self-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Genome-wide association analysis identifies 13 new risk loci for schizophrenia
Multicenter Genetic Studies of Schizophrenia Consortium, Ripke, S., Psychosis Endophenotypes International Consortium, Wellcome Trust Case Control Consortium 2, O'Dushlaine, C., Chambert, K., Moran, J. L., Kähler, A. K., Akterin, S., Bergen, S. E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2742 · Cited by 1,496
Self-citation
Cited by
Items 101–200 of 1,031
Aging of hematopoietic stem cells
de Haan, G., & Lazare, S. S. (2018) · Blood · doi:10.1182/blood-2017-06-746412 · Cited by 432
Therapy-related myeloid neoplasms: when genetics and environment collide
McNerney, M. E., Godley, L. A., & Le Beau, M. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.60 · Cited by 419
Evolutionary Determinants of Cancer
Greaves, M. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0439 · Cited by 395
He, M., Chiang, H.-H., Luo, H., Zheng, Z., Qiao, Q., Wang, L., Tan, M., Ohkubo, R., Mu, W.-C., Zhao, S., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.01.009 · Cited by 425
PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy
Hsu, J. I., Dayaram, T., Tovy, A., De Braekeleer, E., Jeong, M., Wang, F., Zhang, J., Heffernan, T. P., Gera, S., Kovacs, J. J., et al. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.10.004 · Cited by 425
Dynamics of clonal evolution in myelodysplastic syndromes
Makishima, H., Yoshizato, T., Yoshida, K., Sekeres, M. A., Radivoyevitch, T., Suzuki, H., Przychodzen, B., Nagata, Y., Meggendorfer, M., Sanada, M., et al. (2017) · Nature Genetics · doi:10.1038/ng.3742 · Cited by 422
Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations
Loh, P.-R., Genovese, G., Handsaker, R. E., Finucane, H. K., Reshef, Y. A., Palamara, P. F., Birmann, B. M., Talkowski, M. E., Bakhoum, S. F., McCarroll, S. A., et al. (2018) · Nature · doi:10.1038/s41586-018-0321-x · Cited by 423
Self-citationGenetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular Risk in Clonal Hematopoiesis
Bick, A. G., Pirruccello, J. P., Griffin, G. K., Gupta, N., Gabriel, S., Saleheen, D., Libby, P., Kathiresan, S., & Natarajan, P. (2020) · Circulation · doi:10.1161/circulationaha.119.044362 · Cited by 433
Self-citationAssessment of Molecular Relapse Detection in Early-Stage Breast Cancer
Garcia-Murillas, I., Chopra, N., Comino-Méndez, I., Beaney, M., Tovey, H., Cutts, R. J., Swift, C., Kriplani, D., Afentakis, M., Hrebien, S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1838 · Cited by 410
“Results Patient Cohort Primary tumor samples from the 170 patients were sequenced to identify somatic mutations, identifying mutations in 101 patients (mean [SD] age, 54 [11] years), which formed the primary analysis cohort (eFigure 3 and eTable 1 in the Supplement).”
BackgroundSano, S., Oshima, K., Wang, Y., Katanasaka, Y., Sano, M., & Walsh, K. (2018) · Circulation Research · doi:10.1161/circresaha.118.313225 · Cited by 417
Ageing and rejuvenation of tissue stem cells and their niches
Brunet, A., Goodell, M. A., & Rando, T. A. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00510-w · Cited by 407
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Drilon, A., Clark, J. W., Weiss, J., Ou, S.-H. I., Camidge, D. R., Solomon, B. J., Otterson, G. A., Villaruz, L. C., Riely, G. J., Heist, R. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0716-8 · Cited by 395
Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host
Meisel, M., Hinterleitner, R., Pacis, A., Chen, L., Earley, Z. M., Mayassi, T., Pierre, J. F., Ernest, J. D., Galipeau, H. J., Thuille, N., et al. (2018) · Nature · doi:10.1038/s41586-018-0125-z · Cited by 406
Integrative Analysis of Drug Response and Clinical Outcome in Acute Myeloid Leukemia
Bottomly, D., Long, N., Schultz, A. R., Kurtz, S. E., Tognon, C. E., Johnson, K., Abel, M., Agarwal, A., Avaylon, S., Benton, E., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.07.002 · Cited by 403
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study
Takahashi, K., Wang, F., Kantarjian, H., Doss, D., Khanna, K., Thompson, E., Zhao, L., Patel, K., Neelapu, S., Gumbs, C., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30626-x · Cited by 399
“We targeted 32 genes that covered driver mutations detected in t-MN as well as mutations reported as clonal hematopoiesis in previous studies (Supplemental Appendix, page 6).(25, 26, 29) Full details of the sequencing and bioinformatics algorithms are described in Supplemental Appendix (page 4).”
MethodSvensson, E. C., Madar, A., Campbell, C. D., He, Y., Sultan, M., Healey, M. L., Xu, H., D’Aco, K., Fernandez, A., Wache-Mainier, C., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.0386 · Cited by 395
Cai, Z., Kotzin, J. J., Ramdas, B., Chen, S., Nelanuthala, S., Palam, L. R., Pandey, R., Mali, R. S., Liu, Y., Kelley, M. R., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.10.013 · Cited by 394
“TET2 is frequently mutated in patients with myeloid malignancies and these mutations are also present in normal individuals who lack signs of AML but demonstrate clonal hematopoiesis (Busque et al., 2012; Genovese et al., 2014; Jaiswal et al., 2014).”
BackgroundAging Biomarker Consortium, Bao, H., Cao, J., Chen, M., Chen, M., Chen, W., Chen, X., Chen, Y., Chen, Y., Chen, Y., et al. (2023) · Science China Life Sciences · doi:10.1007/s11427-023-2305-0 · Cited by 376
Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease
Jaiswal, S., & Libby, P. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0247-5 · Cited by 386
Dasari, A., Morris, V. K., Allegra, C. J., Atreya, C., Benson, A. B., Boland, P., Chung, K., Copur, M. S., Corcoran, R. B., Deming, D. A., et al. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0392-0 · Cited by 372
Buscarlet, M., Provost, S., Zada, Y. F., Barhdadi, A., Bourgoin, V., Lépine, G., Mollica, L., Szuber, N., Dubé, M.-P., & Busque, L. (2017) · Blood · doi:10.1182/blood-2017-04-777029 · Cited by 383
The cancer epigenome: Concepts, challenges, and therapeutic opportunities
Dawson, M. A. (2017) · Science · doi:10.1126/science.aam7304 · Cited by 377
Kar, S. P., Quiros, P. M., Gu, M., Jiang, T., Mitchell, J., Langdon, R., Iyer, V., Barcena, C., Vijayabaskar, M. S., Fabre, M. A., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01121-z · Cited by 377
Ogawa, S. (2019) · Blood · doi:10.1182/blood-2018-10-844621 · Cited by 367
Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection
Aravanis, A. M., Lee, M., & Klausner, R. D. (2017) · Cell · doi:10.1016/j.cell.2017.01.030 · Cited by 367
“Adding to the specificity challenge are recent reports of somatic alterations accumulating in both solid tissues and the hematopoietic system as a function of age (Genovese et al., 2014; Alexandrov et al., 2015).”
BackgroundThe longitudinal dynamics and natural history of clonal haematopoiesis
Fabre, M. A., de Almeida, J. G., Fiorillo, E., Mitchell, E., Damaskou, A., Rak, J., Orrù, V., Marongiu, M., Chapman, M. S., Vijayabaskar, M. S., et al. (2022) · Nature · doi:10.1038/s41586-022-04785-z · Cited by 374
Inflamm-aging of hematopoiesis, hematopoietic stem cells, and the bone marrow microenvironment
Kovtonyuk, L. V., Fritsch, K., Feng, X., Manz, M. G., & Takizawa, H. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00502 · Cited by 371
Causes and Consequences of Hematopoietic Stem Cell Heterogeneity
Haas, S., Trumpp, A., & Milsom, M. D. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.04.003 · Cited by 344
The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
Vetrie, D., Helgason, G. V., & Copland, M. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0230-9 · Cited by 349
Lee, S. C.-W., Dvinge, H., Kim, E., Cho, H., Micol, J.-B., Chung, Y. R., Durham, B. H., Yoshimi, A., Kim, Y. J., Thomas, M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4097 · Cited by 347
Myeloproliferative Neoplasms: A Contemporary Review
Tefferi, A., & Pardanani, A. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.89 · Cited by 342
Cancer as a disease of old age: changing mutational and microenvironmental landscapes
Laconi, E., Marongiu, F., & DeGregori, J. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0721-1 · Cited by 348
Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA
Schrader, K. A., Cheng, D. T., Joseph, V., Prasad, M., Walsh, M., Zehir, A., Ni, A., Thomas, T., Benayed, R., Ashraf, A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5208 · Cited by 339
Goodell, M. A., & Rando, T. A. (2015) · Science · doi:10.1126/science.aab3388 · Cited by 347
Klco, J. M., Miller, C. A., Griffith, M., Petti, A., Spencer, D. H., Ketkar-Kulkarni, S., Wartman, L. D., Christopher, M., Lamprecht, T. L., Helton, N. M., et al. (2015) · JAMA · doi:10.1001/jama.2015.9643 · Cited by 339
When stem cells grow old: phenotypes and mechanisms of stem cell aging
Schultz, M. B., & Sinclair, D. A. (2016) · Development · doi:10.1242/dev.130633 · Cited by 331
“Furthermore, in both mice and humans, the proportion of differentiated blood cells arising from just a few HSC clones increases, suggesting that the number of active, functional HSCs declines with age (Beerman et al., 2010; Genovese et al., 2014; Jaiswal et al., 2014).”
BackgroundSong, P., Wu, L. R., Yan, Y. H., Zhang, J. X., Chu, T., Kwong, L. N., Patel, A. A., & Zhang, D. Y. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00837-3 · Cited by 319
Somatic inflammatory gene mutations in human ulcerative colitis epithelium
Nanki, K., Fujii, M., Shimokawa, M., Matano, M., Nishikori, S., Date, S., Takano, A., Toshimitsu, K., Ohta, Y., Takahashi, S., et al. (2020) · Nature · doi:10.1038/s41586-019-1844-5 · Cited by 325
van der Pol, Y., & Mouliere, F. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.003 · Cited by 324
Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNγ signaling
Hormaechea-Agulla, D., Matatall, K. A., Le, D. T., Kain, B., Long, X., Kus, P., Jaksik, R., Challen, G. A., Kimmel, M., & King, K. Y. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.03.002 · Cited by 329
Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis
Buch, M. H., Eyre, S., & McGonagle, D. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00541-7 · Cited by 312
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
Moding, E. J., Nabet, B. Y., Alizadeh, A. A., & Diehn, M. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0634 · Cited by 325
Correlation of an epigenetic mitotic clock with cancer risk
Yang, Z., Wong, A., Kuh, D., Paul, D. S., Rakyan, V. K., Leslie, R. D., Zheng, S. C., Widschwendter, M., Beck, S., & Teschendorff, A. E. (2016) · Genome Biology · doi:10.1186/s13059-016-1064-3 · Cited by 325
Kwok, B., Hall, J. M., Witte, J. S., Xu, Y., Reddy, P., Lin, K., Flamholz, R., Dabbas, B., Yung, A., Al-Hafidh, J., et al. (2015) · Blood · doi:10.1182/blood-2015-08-667063 · Cited by 317
Anagnostou, V., Forde, P. M., White, J. R., Niknafs, N., Hruban, C., Naidoo, J., Marrone, K., Sivakumar, I. K. A., Bruhm, D. C., Rosner, S., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1127 · Cited by 318
“However, these approaches have been limited by low sensitivity and specificity of ctDNA methods, with many patients lacking detectable alterations and potential admixture between tumor alterations and those involved in clonal hematopoiesis (33, 34).”
BackgroundAnalysis of error profiles in deep next-generation sequencing data
Ma, X., Shao, Y., Tian, L., Flasch, D. A., Mulder, H. L., Edmonson, M. N., Liu, Y., Chen, X., Newman, S., Nakitandwe, J., et al. (2019) · Genome Biology · doi:10.1186/s13059-019-1659-6 · Cited by 318
“…pathogenic mutations in driver genes such as NRAS / KRAS in leukemias that frequently seed relapse [2], mosaic cancer predisposition mutations [3, 4], age-related clonal hematopoiesis [5] that increases cancer risk, and liquid biopsy for non-invasive diagnosis and disease monitoring [6 – 9].”
BackgroundYi, M., Li, A., Zhou, L., Chu, Q., Song, Y., & Wu, K. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00908-z · Cited by 309
Gillis, N. K., Ball, M., Zhang, Q., Ma, Z., Zhao, Y., Yoder, S. J., Balasis, M. E., Mesa, T. E., Sallman, D. A., Lancet, J. E., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30627-1 · Cited by 317
Molecular biomarkers in acute myeloid leukemia
Prada-Arismendy, J., Arroyave, J. C., & Röthlisberger, S. (2017) · Blood Reviews · doi:10.1016/j.blre.2016.08.005 · Cited by 304
Gorgannezhad, L., Umer, M., Islam, M. N., Nguyen, N.-T., & Shiddiky, M. J. A. (2018) · Lab on a Chip · doi:10.1039/c8lc00100f · Cited by 312
Inflammation-Induced Tumorigenesis and Metastasis
Hibino, S., Kawazoe, T., Kasahara, H., Itoh, S., Ishimoto, T., Sakata-Yanagimoto, M., & Taniguchi, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115421 · Cited by 290
ctDNA as a cancer biomarker: A broad overview
Pessoa, L. S., Heringer, M., & Ferrer, V. P. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103109 · Cited by 298
Marnell, C. S., Bick, A., & Natarajan, P. (2021) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2021.07.004 · Cited by 289
Distinction of lymphoid and myeloid clonal hematopoiesis
Niroula, A., Sekar, A., Murakami, M. A., Trinder, M., Agrawal, M., Wong, W. J., Bick, A. G., Uddin, M. M., Gibson, C. J., Griffin, G. K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01521-4 · Cited by 307
Grob, T., Al Hinai, A. S. A., Sanders, M. A., Kavelaars, F. G., Rijken, M., Gradowska, P. L., Biemond, B. J., Breems, D. A., Maertens, J., van Marwijk Kooy, M., et al. (2022) · Blood · doi:10.1182/blood.2021014472 · Cited by 305
Malcovati, L., Stevenson, K., Papaemmanuil, E., Neuberg, D., Bejar, R., Boultwood, J., Bowen, D. T., Campbell, P. J., Ebert, B. L., Fenaux, P., et al. (2020) · Blood · doi:10.1182/blood.2020004850 · Cited by 297
Thol, F., Gabdoulline, R., Liebich, A., Klement, P., Schiller, J., Kandziora, C., Hambach, L., Stadler, M., Koenecke, C., Flintrop, M., et al. (2018) · Blood · doi:10.1182/blood-2018-02-829911 · Cited by 298
Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
Strickler, J. H., Loree, J. M., Ahronian, L. G., Parikh, A. R., Niedzwiecki, D., Pereira, A. A. L., McKinney, M., Korn, W. M., Atreya, C. E., Banks, K. C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1009 · Cited by 295
“These JAK2 V617F mutations are most likely derived from a hematopoietic clone of indeterminate clinical potential, which is observed sub-clinically in the peripheral blood in a small percentage of the general population, but with increasing prevalence with age (14).”
BackgroundRates, distribution and implications of postzygotic mosaic mutations in autism spectrum disorder
Lim, E. T., Uddin, M., De Rubeis, S., Chan, Y., Kamumbu, A. S., Zhang, X., D'Gama, A. M., Kim, S. N., Hill, R. S., Goldberg, A. P., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4598 · Cited by 299
Self-citationRecent advances in targeted therapies in acute myeloid leukemia
Bhansali, R. S., Pratz, K. W., & Lai, C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01424-6 · Cited by 275
Hallmarks of cardiovascular ageing
Abdellatif, M., Rainer, P. P., Sedej, S., & Kroemer, G. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00881-3 · Cited by 274
The molecular pathogenesis of chronic lymphocytic leukaemia
Fabbri, G., & Dalla-Favera, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.8 · Cited by 286
Caiado, F., Pietras, E. M., & Manz, M. G. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201541 · Cited by 289
Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
Qiu, B., Guo, W., Zhang, F., Lv, F., Ji, Y., Peng, Y., Chen, X., Bao, H., Xu, Y., Shao, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27022-z · Cited by 276
Life histories of myeloproliferative neoplasms inferred from phylogenies
Williams, N., Lee, J., Mitchell, E., Moore, L., Baxter, E. J., Hewinson, J., Dawson, K. J., Menzies, A., Godfrey, A. L., Green, A. R., et al. (2022) · Nature · doi:10.1038/s41586-021-04312-6 · Cited by 285
Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection
Fiala, C., & Diamandis, E. P. (2018) · BMC Medicine · doi:10.1186/s12916-018-1157-9 · Cited by 269
Genomic Instability of iPSCs: Challenges Towards Their Clinical Applications
Yoshihara, M., Hayashizaki, Y., & Murakawa, Y. (2017) · Stem Cell Reviews and Reports · doi:10.1007/s12015-016-9680-6 · Cited by 283
“Somatic mutations, including cancer driver mutations, have been shown to accumulate in blood cells with increasing age [70, 71].”
BackgroundMutations in AML: prognostic and therapeutic implications
DiNardo, C. D., & Cortes, J. E. (2016) · Hematology · doi:10.1182/asheducation-2016.1.348 · Cited by 268
“10% of individuals over age 65, is predominantly defined by the clonal outgrowth of preleukemic clones harboring mutations in one of the genes within this epigenetic class.(34,35) It is likely that mutations in this class of epigenetic modifiers promote clonal outgrowth, but are insufficient to initiate leukemic trans…”
BackgroundAge-related clonal hematopoiesis
Shlush, L. I. (2018) · Blood · doi:10.1182/blood-2017-07-746453 · Cited by 281
Somatic mutations reveal asymmetric cellular dynamics in the early human embryo
Ju, Y. S., Martincorena, I., Gerstung, M., Petljak, M., Alexandrov, L. B., Rahbari, R., Wedge, D. C., Davies, H. R., Ramakrishna, M., Fullam, A., et al. (2017) · Nature · doi:10.1038/nature21703 · Cited by 289
Azad, T. D., Chaudhuri, A. A., Fang, P., Qiao, Y., Esfahani, M. S., Chabon, J. J., Hamilton, E. G., Yang, Y. D., Lovejoy, A., Newman, A. M., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.10.039 · Cited by 266
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes
Sallman, D. A., & List, A. (2019) · Blood · doi:10.1182/blood-2018-10-844654 · Cited by 273
Leukemic stem cells and therapy resistance in acute myeloid leukemia
Stelmach, P., & Trumpp, A. (2023) · Haematologica · doi:10.3324/haematol.2022.280800 · Cited by 241
Cellular and epigenetic drivers of stem cell ageing
Ermolaeva, M., Neri, F., Ori, A., & Rudolph, K. L. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0020-3 · Cited by 272
Increased stem cell proliferation in atherosclerosis accelerates clonal hematopoiesis
Heyde, A., Rohde, D., McAlpine, C. S., Zhang, S., Hoyer, F. F., Gerold, J. M., Cheek, D., Iwamoto, Y., Schloss, M. J., Vandoorne, K., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.049 · Cited by 267
“During aging, progeny of individual HSC clones can begin dominating considerable fractions of the blood, a phenomenon called clonal hematopoiesis (CH) (Genovese et al., 2014; Jaiswal et al., 2014; Xie et al., 2014).”
BackgroundHinds, D. A., Barnholt, K. E., Mesa, R. A., Kiefer, A. K., Do, C. B., Eriksson, N., Mountain, J. L., Francke, U., Tung, J. Y., Nguyen, H. (., et al. (2016) · Blood · doi:10.1182/blood-2015-06-652941 · Cited by 267
“Mutations in TET2 constitute one of the early molecular lesions in myeloid neoplasms, including MPN; similarly, it is one of the more commonly mutated genes in individuals with clonal hematopoiesis.(27-29,52) In the joint analysis results of MPN cases plus V617F carriers vs noncarriers of V617F from the 2 unrelated co…”
BackgroundTherapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia
Uckelmann, H. J., Kim, S. M., Wong, E. M., Hatton, C., Giovinazzo, H., Gadrey, J. Y., Krivtsov, A. V., Rücker, F. G., Döhner, K., McGeehan, G. M., et al. (2020) · Science · doi:10.1126/science.aax5863 · Cited by 257
Diagnosis and Treatment of Myelodysplastic Syndromes: A Review
Sekeres, M. A., & Taylor, J. (2022) · JAMA · doi:10.1001/jama.2022.14578 · Cited by 250
Mosaic Loss of Chromosome y in Blood Is Associated with Alzheimer Disease
Dumanski, J. P., Lambert, J.-C., Rasi, C., Giedraitis, V., Davies, H., Grenier-Boley, B., Lindgren, C. M., Campion, D., Dufouil, C., Pasquier, F., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.05.014 · Cited by 266
Acuna-Hidalgo, R., Sengul, H., Steehouwer, M., van de Vorst, M., Vermeulen, S. H., Kiemeney, L. A. L. M., Veltman, J. A., Gilissen, C., & Hoischen, A. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.05.013 · Cited by 264
TET proteins and the control of cytosine demethylation in cancer
Scourzic, L., Mouly, E., & Bernard, O. A. (2015) · Genome Medicine · doi:10.1186/s13073-015-0134-6 · Cited by 250
“Addressing such questions is important, not only with regard to mutations in genes involved in the control of DNA methylation (such as TET2 or DNMT3A), but also for mutation in genes controlling other functions that predate and may predispose to the development of adult malignancies [125-127].”
BackgroundMacrophage Inflammation, Erythrophagocytosis, and Accelerated Atherosclerosis in Jak2 V617F Mice
Wang, W., Liu, W., Fidler, T., Wang, Y., Tang, Y., Woods, B., Welch, C., Cai, B., Silvestre-Roig, C., Ai, D., et al. (2018) · Circulation Research · doi:10.1161/circresaha.118.313283 · Cited by 262
Nuclear-embedded mitochondrial DNA sequences in 66,083 human genomes
Wei, W., Schon, K. R., Elgar, G., Orioli, A., Tanguy, M., Giess, A., Tischkowitz, M., Caulfield, M. J., & Chinnery, P. F. (2022) · Nature · doi:10.1038/s41586-022-05288-7 · Cited by 246
Mosaicism in health and disease — clones picking up speed
Forsberg, L. A., Gisselsson, D., & Dumanski, J. P. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2016.145 · Cited by 263
Zhang, X., Su, J., Jeong, M., Ko, M., Huang, Y., Park, H. J., Guzman, A., Lei, Y., Huang, Y.-H., Rao, A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3610 · Cited by 258
Guryanova, O. A., Shank, K., Spitzer, B., Luciani, L., Koche, R. P., Garrett-Bakelman, F. E., Ganzel, C., Durham, B. H., Mohanty, A., Hoermann, G., et al. (2016) · Nature Medicine · doi:10.1038/nm.4210 · Cited by 256
Chronic lymphocytic leukaemia: from genetics to treatment
Bosch, F., & Dalla-Favera, R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0239-8 · Cited by 242
Clonal expansion in non-cancer tissues
Kakiuchi, N., & Ogawa, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00335-3 · Cited by 252
Somatic Mutations Increase Hepatic Clonal Fitness and Regeneration in Chronic Liver Disease
Zhu, M., Lu, T., Jia, Y., Luo, X., Gopal, P., Li, L., Odewole, M., Renteria, V., Singal, A. G., Jang, Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.026 · Cited by 250
Pellagatti, A., Armstrong, R. N., Steeples, V., Sharma, E., Repapi, E., Singh, S., Sanchi, A., Radujkovic, A., Horn, P., Dolatshad, H., et al. (2018) · Blood · doi:10.1182/blood-2018-04-843771 · Cited by 244
Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation
Perner, F., Perner, C., Ernst, T., & Heidel, F. H. (2019) · Cells · doi:10.3390/cells8080854 · Cited by 246
Somatic Mutations Reveal Lineage Relationships and Age-Related Mutagenesis in Human Hematopoiesis
Osorio, F. G., Rosendahl Huber, A., Oka, R., Verheul, M., Patel, S. H., Hasaart, K., de la Fonteijne, L., Varela, I., Camargo, F. D., & van Boxtel, R. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.014 · Cited by 252
“In addition, clonal hematopoiesis is commonly observed in elderly and associated with an increased risk of hematologic cancers and death (Genovese et al., 2014; Jaiswal et al., 2014; Xie et al., 2014; Zink et al., 2017); however, the clonal composition of hematopoietic tissue within the normal…”
Targeting innate immunity-driven inflammation in CKD and cardiovascular disease
Speer, T., Dimmeler, S., Schunk, S. J., Fliser, D., & Ridker, P. M. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00621-9 · Cited by 232
White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer
Leal, A., van Grieken, N. C. T., Palsgrove, D. N., Phallen, J., Medina, J. E., Hruban, C., Broeckaert, M. A. M., Anagnostou, V., Adleff, V., Bruhm, D. C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14310-3 · Cited by 244
Loss of Dnmt3a Immortalizes Hematopoietic Stem Cells In Vivo
Jeong, M., Park, H. J., Celik, H., Ostrander, E. L., Reyes, J. M., Guzman, A., Rodriguez, B., Lei, Y., Lee, Y., Ding, L., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.025 · Cited by 243
“But as CHIP is identified by assaying peripheral blood, if DNMT3A mutant human HSCs also show compromised differentiation, we predict the proportion of mutant HSCs in the bone marrow is underestimated by current studies.”
BackgroundInfluentialMosaic loss of chromosome Y is associated with common variation near TCL1A
Zhou, W., Machiela, M. J., Freedman, N. D., Rothman, N., Malats, N., Dagnall, C., Caporaso, N., Teras, L. T., Gaudet, M. M., Gapstur, S. M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3545 · Cited by 242
Hematopoietic Stem Cell Metabolism during Development and Aging
Nakamura-Ishizu, A., Ito, K., & Suda, T. (2020) · Developmental Cell · doi:10.1016/j.devcel.2020.06.029 · Cited by 235
“aging and are detected in 10% of persons older than 65 years of age (Genovese et al., 2014).”
BackgroundMeasurable residual disease testing in acute myeloid leukaemia
Hourigan, C. S., Gale, R. P., Gormley, N. J., Ossenkoppele, G. J., & Walter, R. B. (2017) · Leukemia · doi:10.1038/leu.2017.113 · Cited by 235
Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level
Chen, J., Kao, Y.-R., Sun, D., Todorova, T. I., Reynolds, D., Narayanagari, S.-R., Montagna, C., Will, B., Verma, A., & Steidl, U. (2019) · Nature Medicine · doi:10.1038/s41591-018-0267-4 · Cited by 226
Shih, A. H., Jiang, Y., Meydan, C., Shank, K., Pandey, S., Barreyro, L., Antony-Debre, I., Viale, A., Socci, N., Sun, Y., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.009 · Cited by 236
“…of AML and normal subjects suggests mutations in TET2 and in epigenetic regulators can represent early acquiredmutations in ‘‘pre-leukemic’’ stem cells, which subsequently acquire further mutations leading to overt transformation (Genovese et al., 2014; Jaiswal et al., 2014; Jan et al., 2012).”
Background
Metadata
- Authors
- Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., Purcell, S. M., Svantesson, O., Landén, M., Höglund, M., Lehmann, S., Gabriel, S. B., Moran, J. L., Lander, E. S., Sullivan, P. F., Sklar, P., Grönberg, H., Hultman, C. M., & McCarroll, S. A.
- Affiliations
- Harvard University (US)
- Karolinska Institutet (SE)
- Science for Life Laboratory (SE)
- Stanley Center for Psychiatric Research (US)
- Memorial Sloan Kettering Cancer Center (US)
- Massachusetts General Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Gothenburg (SE)
- Uppsala University Hospital (SE)
- Karolinska University Hospital (SE)
- Broad Institute (US)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Genovese, Giulio
- Kähler, Anna K.
- Handsaker, Robert E.
- Lindberg, Johan
- Rose, Samuel A.
- Bakhoum, Samuel F.
- Mick, Eran
- Neale, Benjamin M.
- Fromer, Menachem
- Purcell, Shaun M.
- Landén, Mikael
- Höglund, Martin
- Lehmann, Sören
- Gabriel, Stacey B.
- Moran, Jennifer L.
- Lander, Eric S.
- Sullivan, Patrick F.
- Sklar, Pamela
- Grönberg, Henrik
- McCarroll, Steven A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-25
- Volume
- 371
- Issue
- 26
- Pages
- 2477-2487
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4290021
- OpenAlex
- W2126816979
- Cited by
- 3,531
- References
- 40
- Citations by year
- 2026: 240 · 2025: 293 · 2024: 315 · 2023: 363 · 2022: 386 · 2021: 360 · 2020: 356 · 2019: 310 · 2018: 294 · 2017: 254 · 2016: 215 · 2015: 134 · 2014: 6
- FWCI
- 143.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH077139, RC2MH089905)
- National Human Genome Research Institute (R01HG006855, U54HG003067, R01HG005827)
- National Cancer Institute (P30CA014051)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Keywords
- clonal hematopoiesis, somatic mutations, DNMT3A, ASXL1, TET2, acute myeloid leukemia, early cancer detection, bone marrow biopsy, cancer susceptibility
- MeSH terms
- Adult, Age Factors, Aged, Aged, 80 and over, Blood, Cell Transformation, Neoplastic, Clone Cells, DNA Mutational Analysis, Hematopoiesis, Hematopoietic Stem Cells, Humans, Middle Aged, Mutation, Risk Factors, Hematologic Neoplasms, Young Adult, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.